Wednesday, November 18, 2009

Clinical Data’s cardiac stress test hits Phase 3 trials

By Mass High Tech staff

Video Gallery

Funding drugs for rare diseases

MHT's Julie Donnelly: Life science startups finding investments

MHT's Marc Songini: Technology to keep seniors healthy

Related News

Nyer Medical delisting paves way for dissolution [February 9, 2010]

Olympics to use Billerica firm’s medical device [February 8, 2010]

Northeastern's Torchilin lands $1.4M NIH award [February 5, 2010]

Tepha pulls in $3M for medical biomaterials [February 4, 2010]

Inverness buys Kroll substance abuse unit for $110M [February 4, 2010]

Clinical Data Inc. has begun a Phase 3 trial of its cardiac stress testing agent, Stedivaze, in detecting defects to supplying blood to the heart. The trial is intended to compare the agent to adenosine in myocardial perfusion imaging.

The randomized trial is being conducted with about 750 patients in a time period of up to two years. In addition to running a comparison between Stedivaze and adenosine, it will also analyze cases of side effects such as cheest pain, dizziness, shortness of breath and headache.

Newton-based Clinical Data (Nasdaq: CLDA) announced on Tuesday that it has formed a scientific advisory board for its PGxHealth division, which develops the Familion line of genetic tests.